Meridian Bioscience Stock

Meridian Bioscience EBIT

The EBIT of Meridian Bioscience (VIVO) as of Jul 16, 2026 is 75.60 M USD. In the previous year, EBIT was 101.83 M USD — a change of -25.75% (lower).

EBIT

75.60 MUSD

YoY

-25.75%

Last updated:

In 2026, Meridian Bioscience's EBIT was 75.60 M USD, a -25.75% increase from the 101.83 M USD EBIT recorded in the previous year.

The Meridian Bioscience EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2018
44.70 base
Jan 1, 2019
38.90 base
Jan 1, 2020
68.00 base
Jan 1, 2021
101.83 base
Jan 1, 2022
75.60 base
Jan 1, 2023 (e)
46.97 base
Jan 1, 2024 (e)
32.45 base
Jan 1, 2025 (e)
22.86 base
YEAREBIT (M USD)
2025 est 22.86
2024 est 32.45
2023 est 46.97
2022 75.60
2021 101.83
2020 68.00
2019 38.90
2018 44.70
2017 44.80
2016 53.60
2015 56.10
2014 52.40
2013 57.30
2012 50.30
2011 41.80
2010 41.10
2009 48.80
2008 44.40
2007 35.00
2006 26.90
2005 20.30
2004 14.70
2003 12.80
Access this data via the Eulerpool API

Meridian Bioscience Revenue

Meridian Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
213.60 M USD
44.70 M USD
23.80 M USD
Jan 1, 2019
201.00 M USD
38.90 M USD
24.40 M USD
Jan 1, 2020
253.70 M USD
68.00 M USD
46.20 M USD
Jan 1, 2021
317.90 M USD
101.83 M USD
71.41 M USD
Jan 1, 2022
333.02 M USD
75.60 M USD
42.46 M USD
Jan 1, 2023 (e)
294.11 M USD
46.97 M USD
37.34 M USD
Jan 1, 2024 (e)
302.36 M USD
32.45 M USD
26.22 M USD
Jan 1, 2025 (e)
300.53 M USD
22.86 M USD
18.78 M USD

Meridian Bioscience Margins

Meridian Bioscience stock margins

The Meridian Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Meridian Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Meridian Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
61.33 %
20.93 %
11.14 %
Jan 1, 2019
59.05 %
19.35 %
12.14 %
Jan 1, 2020
61.57 %
26.80 %
18.21 %
Jan 1, 2021
63.27 %
32.03 %
22.46 %
Jan 1, 2022
56.56 %
22.70 %
12.75 %
Jan 1, 2023 (e)
56.56 %
15.97 %
12.70 %
Jan 1, 2024 (e)
56.56 %
10.73 %
8.67 %
Jan 1, 2025 (e)
56.56 %
7.61 %
6.25 %

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Meridian Bioscience's EBIT

Meridian Bioscience's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Meridian Bioscience's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Meridian Bioscience's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Meridian Bioscience’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Meridian Bioscience stock

EBIT of Meridian Bioscience is 75.60 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Meridian Bioscience

All Key Metrics — Meridian Bioscience